Sign up


Match Document Document Title
8679540 Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications  
The present invention relates to novel pharmaceutical formulations based on aqueous colloidal suspensions for the prolonged release of one or more active principles, and to the applications,...
8679762 Method of detecting hepatitis B virus s antigen  
[PROBLEMS] To provide a probe useful in the detection of HBV or HBs antigen by which an escape mutant of hepatitis B virus (HBV) possibly occurring in a specimen can be detected; and a method of...
8679489 Inhibiting cell migration  
Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the ...
8679488 Targeting of bone marrow neovasculature  
Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid...
8679485 Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis  
The present disclosure provides methodology and compositions for preventing and treating various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using an...
8679487 Anti-interleukin-4 receptor antibodies  
Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are...
8674078 Methods of using BTL-II proteins  
The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using...
8674079 Cancer cell migration and cancer cell invasion inhibitor  
Provided are an antibody which binds specifically PAR1 (protease activated receptor 1) or a fragment of the antibody which retains similar characteristics thereto; a composition containing the same...
8673309 Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1  
A method of detecting MSDX Complex-1, the method introducing a first antibody to a sample to create an antibody-sample mixture, wherein the first antibody is specific for one of fibrinogen,...
8673305 Methods of treatment with antibodies against the extracellular loops of C5aR  
The present invention relates to antibodies which bind to C5aR and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular...
8673300 Therapeutic compositions and methods for the prevention of autoimmune diseases  
Antibodies specific for an MHC class II-autoantigen complex.
8673298 Stabilized compositions of proteins having a free thiol moeity  
Compositions of proteins having free thiols, and methods of making and using such compositions, are described.
8673308 Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseases  
Methods and therapeutic agents are disclosed for treating neurodegenerative disorders by depletion of CD8 positive T cells by using antibodies, FAb fragments of antibodies or similar agents that...
8673581 sCD40L and placental growth factor (PLGF) as biochemical marker combinations in cardiovascular diseases  
The invention relates to novel markers of vascular inflammation and combinations thereof as diagnostic and prognostic tools in patients with cardiovascular diseases. The markers also act as tools...
8673299 Anti-RANTES antibodies  
The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, CCL5),...
8668909 Anti MIF antibodies  
The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor...
8668910 Antibodies that specifically bind to the EphA2 receptor  
The present disclosure relates to an antibody or an epitope-binding fragment thereof that specifically binds to an EphA2 receptor. It further relates to a conjugate comprising a cytotoxic agent...
8668908 Method for alleviating chemotherapy side effects using extract of Dioscorea sp  
Extract fractions of Dioscorea sp. and methods of preparing the extract fractions are disclosed. The extract fractions enhance the proliferation and differentiation of bone marrow cells. Also...
8663641 Anti-PSGL-1 antibodies  
Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of...
8663636 Method of treating a malignant tumor by administering antibodies directed to DLL4  
The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described...
8664363 Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease  
Provided herein are chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7, which comprise human or humanized framework regions of the immunoglobulin heavy chain variable...
8664362 Humanized and chimeric anti-properdin antibodies  
An isolated anti-properdin antibody or antigen binding portion thereof includes a heavy chain variable domain including the 3CDRs in SEQ ID NO: 1 and light chain variable domain including the 3...
8664470 Mouse model of retinal degeneration  
The invention is directed to a method of producing a non-human mammal having one or more pathological characteristics of retinal degeneration and/or age-related macular degeneration. In particular,...
8663635 N-cadherin: target for cancer diagnosis and therapy  
The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that express N-cadherin, including prostrate and bladder cancers.
8663576 Detection of intraamniotic infection  
The present invention concerns the identification of biomarkers and groups or combinations of biomarkers that can be used for non-invasive diagnosis of intra-amniotic infection, and diagnostic...
8663634 Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity  
The present invention provides methods of treating, preventing or ameliorating the symptoms of T cell-mediated immunological diseases, particularly autoimmune diseases, through the use of anti-CD3...
8663637 Methods and compositions for modulation of Olfml3 mediated angiogenesis  
The present invention relates to antibodies against specific domains of Olfml3 and the use of such in angiogenesis. In particular aspects, angiogenesis-related conditions, such as cancer, can be...
8658169 Antibodies against IL-25  
The present invention relates to IL-25 antibody VH domains and target binding members (e.g., antibodies) that comprise such antibody VH domains and bind IL-25. The invention also relates to...
8658164 Methods and materials for the diagnosis of prostate cancers  
Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample...
8658167 Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis  
Provided are methodology, compositions and kits to prevent and treat diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, using processed lysyl oxidase or lysyl...
8658168 Compositions and methods for homoconjugates of antibodies which induce growth arrest of apoptosis of tumor cells  
This invention discloses monoclonal antibodies (MAbs) which have little or no signaling activity as monomers become potent anti-tumor agents when they are converted into homoconjugates. The...
8658165 Method of treating aberrant mucus production in respiratory disease  
The present invention relates to modulators of the Neuregulin (NRG) family, particularly NRG1 and more particularly NRG1β, and most particularly NRG1β1. The present invention also relates to the u...
8658166 Methods and materials for the diagnosis of prostate cancers  
Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample...
8658771 Humanized antibodies against human interferon-alpha  
The present invention provides humanized anti-human IFN-α monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ...
8658380 Diagnostic and therapeutic target  
The present invention relates to an in vitro method for assessing the risk that a subject suffers from a cancer, comprising measuring the expression level of Proline/arginine-rich end leucine...
8652474 Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof  
A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and...
8652465 Methods and compositions for the treatment of persistent infections  
The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and...
8652790 Conformational entropy in molecular recognition  
The present invention provides methods for the determination of the degree of molecular recognition of a protein with a ligand, including a first protein with a second protein. The methods may...
8652466 Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting  
The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies),...
8652468 Methods of binding TNF-α using anti-TNF-α antibody fragment-polymer conjugates  
Described are conjugates formed by an antibody fragment covalently attached to a nonproteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates...
8652789 Diagnosis and prognosis of dipeptidyl peptidase-associated disease states  
A method is provided for the diagnosis or prognosis of a disease state, involving the measurement of a parameter of discriminated dipeptidyl dipeptidases from a patient sample, and the correlation...
8652469 M-CSF-specific monoclonal antibody and uses thereof  
M-CSF-specific RX1-based or RX-I derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of...
8652467 Dek protein compositions and methods of using the same  
The present invention relates to DEK protein compositions (e.g., antibodies, small molecule inhibitors, siRNAs) and methods of using the same. In particular, the present invention provides...
8652476 Pharmaceutical composition for treating ischemic events  
Methods and pharmaceutical compositions for treating severe ischemic events including cerebral infarction, cardiac infarction, or pulmonary embolism, comprising a thrombolytic intervention...
8647625 Anti-CD154 antibodies  
The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared...
8647626 Compositions comprising TNF-specific antibodies for oral delivery  
In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered...
8647624 Treatment of immune disorders with anti-CD70 antibody  
Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as...
8647636 Low antigen-dose immunization utilizing overlapping peptides for maximizing T-helper cell 1 (Th1) immunity against a pathogen  
Disclosed are compositions, kits, and methods for inducing an immune response against disease. The dosage of antigen contained or utilized in the presently disclosed compositions, kits, and methods...
8642032 Method for screening of patient to be administered with pharmaceutical agent comprising anti-cancer antibody as active ingredient  
The present invention provides a method for screening a patient to be administered with a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient, said method...
8642036 Treatment with anti-ErbB2 antibodies  
The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or...